ProKidney Completes Enrollment for Pivotal Kidney Therapy Trial
On August 10, ProKidney Corp. (NASDAQ:PROK) announced the completion of enrollment in its Phase 3 PROACT 1 trial evaluating rilparencel, a cell therapy aimed at slowing kidney function decline in patients with chronic kidney disease and type 2 diabetes. The company expects topline results by Q2 2027, which could determine if the treatment is eligible for accelerated approval. The broader study includes around 470 participants and will provide confirmatory data expected as late as mid-2029. ProKidney also announced a key hire in June—Kenneth Locke—as Chief Technical Officer to build out manufacturing infrastructure ahead of potential regulatory success. However, the company's cash reserves have dropped significantly due to rising R&D costs. With only $181.6 million remaining and operations expected to last until mid-2027, ProKidney faces a tight timeline where any delay could lead to financial strain before results are available.
Tickers: $PROK
Topics: biotech cell_therapy chronic_kidney_disease drug_development